Treatment of alveolar osteitis using ozonated water - Treatment of alveolar osteitis using ozonated water

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-007024-34-CZ

Enrollment

100

Registered

2009-10-30

Start date

2009-12-28

Completion date

Unknown

Last updated

2016-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complication after tooth extraction - alveolar osteitis (dry socket). There is no causal treatment of alveolar osteitis. That’s why symptomatic therapy is used. Disinfectants are the most important agents for standard treatment of this disorder. Ozone is one of these substances. It is proved to be very efficient in wound healing in medicine. MedDRA version: 9.1 Level: LLT Classification code 10013787 Term: Dry socket MedDRA version: 12.0 Level: LLT Classification code 10013787 Term: Dry socket

Interventions

Product Name: Ozonized water Product Code: Ozonized water Pharmaceutical Form: Oral solution INN or Proposed INN: Ozone CAS Number: 10028-15-6 Concentration unit: mg/l milligram(s)/litre Concentration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion ctiteria involve patients: - accountable men and women from 18 to 65 years old with diagnosed dry socket - who are treated with diagnosis of dry socket at maxillofacial outpatient department, - who do not administer antimicrobial and antiinflammatory drugs because of other disorders Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Exclusion criteria involve patients: - under 18 years of age - pregnant and nursing women - who administer antimicrobial and antiinflammatory drugs because of other disorders - with diagnosed hyperthyreosis, diabetes mellitus and bleeding disorders - who receive antiagregant, anticoagulative and immunosupressive treatment

Design outcomes

Primary

Measure	Time frame
Main Objective: The main objective of this project is to evaluate a healing period of dry socket using ozone solution in water.;Secondary Objective: Other objectives are to decrease the recover period, to reduce subjective problems and to increase economic efficiency of therapy: decrease duration of disability reduction of drugs administration used in standard therapy;Primary end point(s): Allevation of subjective sympthoms of the patient (pain, oral malodour) and normalization of patient's objective status evaluated by an investigator (allevation of local and general signs of the disorder, e.g. swelling, erythema, oral malodour, reactive inflammation of lymphatic nodes, general health state)	—

Measure

Time frame

Main Objective: The main objective of this project is to evaluate a healing period of dry socket using ozone solution in water.;Secondary Objective: Other objectives are to decrease the recover period, to reduce subjective problems and to increase economic efficiency of therapy: decrease duration of disability reduction of drugs administration used in standard therapy;Primary end point(s): Allevation of subjective sympthoms of the patient (pain, oral malodour) and normalization of patient's objective status evaluated by an investigator (allevation of local and general signs of the disorder, e.g. swelling, erythema, oral malodour, reactive inflammation of lymphatic nodes, general health state)

—

Countries

Czech Republic

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026